Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder.

Serra DB, Affrime MB, Bedigian MP, Greig G, Milosavljev S, Skerjanec A, Wang Y.

J Clin Pharmacol. 2005 Sep;45(9):1038-47.

PMID:
16100298
2.

Assessment of a multiple-dose drug interaction between ezetimibe, a novel selective cholesterol absorption inhibitor and gemfibrozil.

Reyderman L, Kosoglou T, Statkevich P, Pember L, Boutros T, Maxwell SE, Affrime M, Batra V.

Int J Clin Pharmacol Ther. 2004 Sep;42(9):512-8.

PMID:
15487810
3.

Single-dose pharmacokinetics and tolerability of pegylated interferon-alpha2b in young and elderly healthy subjects.

Gupta SK, Glue P, Jacobs S, Belle D, Affrime M.

Br J Clin Pharmacol. 2003 Jul;56(1):131-4.

4.

Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic-pharmacodynamic models.

Jen J, Laughlin M, Chung C, Heft S, Affrime MB, Gupta SK, Glue P, Hajian G.

Clin Pharmacol Ther. 2002 Oct;72(4):349-61.

PMID:
12386637
5.

Single-dose pharmacokinetics and safety of pegylated interferon-alpha2b in patients with chronic renal dysfunction.

Gupta SK, Pittenger AL, Swan SK, Marbury TC, Tobillo E, Batra V, Sack M, Glue P, Jacobs S, Affrime M.

J Clin Pharmacol. 2002 Oct;42(10):1109-15.

PMID:
12362925
6.

Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin.

Kosoglou T, Meyer I, Veltri EP, Statkevich P, Yang B, Zhu Y, Mellars L, Maxwell SE, Patrick JE, Cutler DL, Batra VK, Affrime MB.

Br J Clin Pharmacol. 2002 Sep;54(3):309-19.

7.

Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole.

Banfield C, Herron J, Keung A, Padhi D, Affrime M.

Clin Pharmacokinet. 2002;41 Suppl 1:37-44.

PMID:
12169045
8.

Lack of clinically relevant interaction between desloratadine and erythromycin.

Banfield C, Hunt T, Reyderman L, Statkevich P, Padhi D, Affrime M.

Clin Pharmacokinet. 2002;41 Suppl 1:29-35.

PMID:
12169044
9.

Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine.

Affrime M, Banfield C, Gupta S, Cohen A, Boutros T, Thonoor M, Cayen M.

Clin Pharmacokinet. 2002;41 Suppl 1:21-8.

PMID:
12169043
10.

A pharmacokinetic profile of desloratadine in healthy adults, including elderly.

Affrime M, Gupta S, Banfield C, Cohen A.

Clin Pharmacokinet. 2002;41 Suppl 1:13-9.

PMID:
12169042
11.

Oral bioavailability of desloratadine is unaffected by food.

Gupta S, Banfield C, Affrime M, Marbury T, Padhi D, Glue P.

Clin Pharmacokinet. 2002;41 Suppl 1:7-12.

PMID:
12169041
12.

Desloratadine demonstrates dose proportionality in healthy adults after single doses.

Gupta S, Banfield C, Affrime M, Marco A, Cayen M, Herron J, Padhi D.

Clin Pharmacokinet. 2002;41 Suppl 1:1-6.

PMID:
12169040
13.

Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine.

Banfield C, Gupta S, Marino M, Lim J, Affrime M.

Clin Pharmacokinet. 2002;41(4):311-8.

PMID:
11978146
14.

Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects.

Patrick JE, Kosoglou T, Stauber KL, Alton KB, Maxwell SE, Zhu Y, Statkevich P, Iannucci R, Chowdhury S, Affrime M, Cayen MN.

Drug Metab Dispos. 2002 Apr;30(4):430-7.

PMID:
11901097
15.

Systemic bioavailability of inhaled corticosteroids: appropriate and comparable methodology.

Affrime MB, Banfield C, Nolop K.

Eur Respir J. 2001 Jul;18(1):246. No abstract available.

16.

Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study.

Gupta S, Banfield C, Kantesaria B, Marino M, Clement R, Affrime M, Batra V.

Clin Ther. 2001 Mar;23(3):451-66.

PMID:
11318079
17.

Regional lung deposition of a technetium 99m-labeled formulation of mometasone furoate administered by hydrofluoroalkane 227 metered-dose inhaler.

Pickering H, Pitcairn GR, Hirst PH, Bacon PR, Newman SP, Affrime MB, Marino M.

Clin Ther. 2000 Dec;22(12):1483-93.

PMID:
11192139
18.

Population pharmacokinetics of temozolomide in cancer patients.

Jen JF, Cutler DL, Pai SM, Batra VK, Affrime MB, Zambas DN, Heft S, Hajian G.

Pharm Res. 2000 Oct;17(10):1284-9.

PMID:
11145236
19.
20.

Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses.

Affrime MB, Kosoglou T, Thonoor CM, Flannery BE, Herron JM.

Chest. 2000 Dec;118(6):1538-46.

PMID:
11115437
21.

Bioavailability and metabolism of mometasone furoate following administration by metered-dose and dry-powder inhalers in healthy human volunteers.

Affrime MB, Cuss F, Padhi D, Wirth M, Pai S, Clement RP, Lim J, Kantesaria B, Alton K, Cayen MN.

J Clin Pharmacol. 2000 Nov;40(11):1227-36.

PMID:
11075308
22.

The pharmacokinetics, electrocardiographic effects, and tolerability of loratadine syrup in children aged 2 to 5 years.

Salmun LM, Herron JM, Banfield C, Padhi D, Lorber R, Affrime MB.

Clin Ther. 2000 May;22(5):613-21.

PMID:
10868558
23.

In vivo effects of interleukin-10 on human cytochrome P450 activity.

Gorski JC, Hall SD, Becker P, Affrime MB, Cutler DL, Haehner-Daniels B.

Clin Pharmacol Ther. 2000 Jan;67(1):32-43.

PMID:
10668851
24.

Disposition of recombinant human interleukin-10 in subjects with various degrees of renal function.

Andersen SR, Lambrecht LJ, Swan SK, Cutler DL, Radwanski E, Affrime MB, Garaud JJ.

J Clin Pharmacol. 1999 Oct;39(10):1015-20.

PMID:
10516935
25.

The penetration of ceftibuten into the respiratory tract.

Krumpe P, Lin CC, Radwanski E, Cayen MN, Affrime MB.

Chest. 1999 Aug;116(2):369-74.

PMID:
10453864
26.

Cardiovascular profile of loratadine.

Hey JA, Affrime M, Cobert B, Kreutner W, Cuss FM.

Clin Exp Allergy. 1999 Jul;29 Suppl 3:197-9. Review.

PMID:
10444237
27.

Cardiovascular safety of second-generation antihistamines.

Barbey JT, Anderson M, Ciprandi G, Frew AJ, Morad M, Priori SG, Ongini E, Affrime MB.

Am J Rhinol. 1999 May-Jun;13(3):235-43.

PMID:
10392245
28.
29.

Pharmacokinetics of flutamide in patients with renal insufficiency.

Anjum S, Swan SK, Lambrecht LJ, Radwanski E, Cutler DL, Affrime MB, Halstenson CE.

Br J Clin Pharmacol. 1999 Jan;47(1):43-7.

30.

Pharmacokinetics and leukocyte responses of recombinant human interleukin-10.

Radwanski E, Chakraborty A, Van Wart S, Huhn RD, Cutler DL, Affrime MB, Jusko WJ.

Pharm Res. 1998 Dec;15(12):1895-901.

PMID:
9892475
31.

Disposition of 14C-eptifibatide after intravenous administration to healthy men.

Alton KB, Kosoglou T, Baker S, Affrime MB, Cayen MN, Patrick JE.

Clin Ther. 1998 Mar-Apr;20(2):307-23.

PMID:
9589822
32.

Single-dose pharmacokinetics of isepamicin in young and geriatric volunteers.

Nomeir AA, Radwanski E, Cutler D, Affrime M, Christopher D, Korduba C, Batra V, Lin CC, Cayen MN.

J Clin Pharmacol. 1997 Nov;37(11):1021-30.

PMID:
9505995
33.

A systemic bioactivity comparison of double-strength and regular-strength beclomethasone dipropionate MDI formulations.

Brannan MD, Herron JM, Reidenberg P, Affrime MB.

Ann Allergy Asthma Immunol. 1998 Jan;80(1):39-44.

PMID:
9475565
34.

Safety and tolerability of once-daily mometasone furoate aqueous nasal spray in children.

Brannan MD, Herron JM, Affrime MB.

Clin Ther. 1997 Nov-Dec;19(6):1330-9.

PMID:
9444443
35.
36.

Activity and tolerance of a continuous subcutaneous infusion of interferon-alpha2b in patients with chronic hepatitis C.

Schenker S, Cutler D, Finch J, Tamburro CH, Affrime M, Sabo R, Bay M.

J Interferon Cytokine Res. 1997 Nov;17(11):665-70.

PMID:
9402104
37.

Pharmacodynamics of subcutaneous recombinant human interleukin-10 in healthy volunteers.

Huhn RD, Radwanski E, Gallo J, Affrime MB, Sabo R, Gonyo G, Monge A, Cutler DL.

Clin Pharmacol Ther. 1997 Aug;62(2):171-80.

PMID:
9284853
38.

Single and multiple dose pharmacokinetics of felbamate in the elderly.

Richens A, Banfield CR, Salfi M, Nomeir A, Lin CC, Jensen P, Affrime MB, Glue P.

Br J Clin Pharmacol. 1997 Aug;44(2):129-34.

39.

Pharmacokinetics of isepamicin following a single administration by intravenous infusion or intramuscular injections.

Radwanski E, Batra V, Cayen M, Korduba C, Cutler D, Affrime M, Nomeir A, Lin CC.

Antimicrob Agents Chemother. 1997 Aug;41(8):1794-6.

40.

Single-dose pharmacokinetics of felbamate in patients with renal dysfunction.

Glue P, Sulowicz W, Colucci R, Banfield C, Pai S, Lin C, Affrime MB.

Br J Clin Pharmacol. 1997 Jul;44(1):91-3.

41.

Interleukin-10 inhibits activation of coagulation and fibrinolysis during human endotoxemia.

Pajkrt D, van der Poll T, Levi M, Cutler DL, Affrime MB, van den Ende A, ten Cate JW, van Deventer SJ.

Blood. 1997 Apr 15;89(8):2701-5.

PMID:
9108387
42.

Attenuation of proinflammatory response by recombinant human IL-10 in human endotoxemia: effect of timing of recombinant human IL-10 administration.

Pajkrt D, Camoglio L, Tiel-van Buul MC, de Bruin K, Cutler DL, Affrime MB, Rikken G, van der Poll T, ten Cate JW, van Deventer SJ.

J Immunol. 1997 Apr 15;158(8):3971-7.

PMID:
9103468
43.

Pharmacokinetics of intramuscularly administered isepamicin in man.

Lin CC, Radwanski E, Korduba C, Affrime M, Cayen MN.

Chemotherapy. 1997 Mar-Apr;43(2):86-93.

PMID:
9084916
44.

Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers.

Nix DE, Symonds WT, Hyatt JM, Wilton JH, Teal MA, Reidenberg P, Affrime MB.

Pharmacotherapy. 1997 Jan-Feb;17(1):121-5.

PMID:
9017772
45.

Pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor: the effects of zidovudine.

Aweeka FT, Kwong M, Mak M, al-Uzri A, Affrime M, Cutler D, Kahn J, Gambertoglio JG.

J Clin Pharmacol. 1996 Dec;36(12):1107-13.

PMID:
9013366
46.

Comparative bioavailability of ceftibuten in capsule and suspension forms.

Lin CC, Affrime M, Radwanski E, Lim J, Colucci R, Cayen MN.

Clin Ther. 1996 Nov-Dec;18(6):1139-49.

PMID:
9001830
47.

Influence of food on the oral bioavailability of loratadine and pseudoephedrine from extended-release tablets in healthy volunteers.

Nomeir AA, Mojaverian P, Kosoglou T, Affrime MB, Nezamis J, Rodwanski E, Lin CC, Cayen MN.

J Clin Pharmacol. 1996 Oct;36(10):923-30.

PMID:
8930779
48.

Clinical, hematologic, and immunologic effects of interleukin-10 in humans.

Fuchs AC, Granowitz EV, Shapiro L, Vannier E, Lonnemann G, Angel JB, Kennedy JS, Rabson AR, Radwanski E, Affrime MB, Cutler DL, Grint PC, Dinarello CA.

J Clin Immunol. 1996 Sep;16(5):291-303.

PMID:
8886999
49.

Effect of felbamate on the pharmacokinetics of lamotrigine.

Colucci R, Glue P, Holt B, Banfield C, Reidenberg P, Meehan JW, Pai S, Nomeir A, Lim J, Lin CC, Affrime MB.

J Clin Pharmacol. 1996 Jul;36(7):634-8.

PMID:
8844446
50.

Effect of Felbamate on The Pharmacokinetics of Clonazepam.

Colucci R, Glue P, Banfield C, Reidenberg P, Meehan J, Radwanski E, Korduba C, Lin C, Dogterom P, Ebels T, Hendriks G, Jonkman J, Affrime M.

Am J Ther. 1996 Apr;3(4):294-297.

PMID:
11862264

Supplemental Content

Loading ...
Support Center